Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: Establishing efficacy of and molecular pathways for statins has the potential to impact incidence of Alzheimer's and age‐related neurodegenerative diseases (NDD). Methods: This retrospective cohort study surveyed US‐based Humana claims, which includes prescription and patient records from private‐payer and Medicare insurance. Claims from 288,515 patients, aged 45 years and older, without prior history of NDD or neurological surgery, were surveyed for a diagnosis of NDD starting 1 year following statin exposure. Patients were required to be enrolled with claims data for at least 6 months prior to first statin prescription and at least 3 years thereafter. Computational system biology analysis was conducted to determine unique target engagement for each statin. Results: Of the 288,515 participants included in the study, 144,214 patients (mean [standard deviation (SD)] age, 67.22 [3.8] years) exposed to statin therapies, and 144,301 patients (65.97 [3.2] years) were not treated with statins. The mean (SD) follow‐up time was 5.1 (2.3) years. Exposure to statins was associated with a lower incidence of Alzheimer's disease (1.10% vs 2.37%; relative risk [RR], 0.4643; 95% confidence interval [CI], 0.44–0.49; P < .001), dementia 3.03% vs 5.39%; RR, 0.56; 95% CI, 0.54–0.58; P < .001), multiple sclerosis (0.08% vs 0.15%; RR, 0.52; 95% CI, 0.41–0.66; P < .001), Parkinson's disease (0.48% vs 0.92%; RR, 0.53; 95% CI, 0.48–0.58; P < .001), and amyotrophic lateral sclerosis (0.02% vs 0.05%; RR, 0.46; 95% CI, 0.30–0.69; P < .001). All NDD incidence for all statins, except for fluvastatin (RR, 0.91; 95% CI, 0.65‐1.30; P = 0.71), was reduced with variances in individual risk profiles. Pathway analysis indicated unique and common profiles associated with risk reduction efficacy. Discussion: Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at‐risk NDD populations. Common statin activated pathways indicate overarching systems required for risk reduction whereas unique targets could advance a precision medicine approach to prevent neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
The changing prevalence and incidence of dementia over time - current evidence
Wu, Y.-T., Beiser, A. S., Breteler, M. M. B., Fratiglioni, L., Helmer, C., Hendrie, H. C., Honda, H., Ikram, M. A., Langa, K. M., Lobo, A., et al. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.63 · Cited by 775
Stroke and dementia risk: A systematic review and meta‐analysis
Kuźma, E., Lourida, I., Moore, S. F., Levine, D. A., Ukoumunne, O. C., & Llewellyn, D. J. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3061 · Cited by 376
Wolters, F. J., Segufa, R. A., Darweesh, S. K. L., Bos, D., Ikram, M. A., Sabayan, B., Hofman, A., & Sedaghat, S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.007 · Cited by 293
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
Self-citation
Cited by
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01038-3 · Cited by 73
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Du, Y., Yu, Z., Li, C., Zhang, Y., & Xu, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1473796 · Cited by 13
Cortes-Flores, H., Torrandell-Haro, G., & Brinton, R. D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1358568 · Cited by 12
Self-citation
Metadata
- Authors
- Torrandell‐Haro, G., Branigan, G. L., Vitali, F., Geifman, N., Zissimopoulos, J. M., & Brinton, R. D.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 6
- Issue
- 1
- Pages
- e12108-e12108
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W3110411991
- Cited by
- 79
- References
- 13
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases. https://app.cochat.ai/papers/10.1002/trc2.12108
- The paper
- Torrandell‐Haro, G., Branigan, G. L., Vitali, F., Geifman, N., Zissimopoulos, J. M., & Brinton, R. D. (2020). Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1002/trc2.12108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.